位于美国佛蒙特州和纽约州的连锁药房Kinney Drugs在5月部署了一款名为Burt的AI虚拟助手，用于处理处方配药和患者沟通[1]。这一由第三方公司Synerio开发的系统旨在提高运营效率，但上线后暴露出多个严重问题[1]。
客户投诉表明该AI工具存在药物信息不准确、剂量错误、处理延迟和隐私泄露风险等问题[1]。许多患者报告称与虚拟助手的交互体验不佳且无实际帮助价值，部分顾客因隐私忧虑已转向其他药房[1]。根据Kinney Drugs的隐私政策，客户的受保护健康信息可能被用于改进AI工具和药房运营[1]，而这些隐私条款分散在11份不同的文件中[1]。
美国公民自由联盟高级律师Cody Venzke表示，科技发展步伐已经超越监管框架[1]。佛蒙特州已在6月16日由州长Phil Scott签署了数据隐私法案S.71，该法案将在两年后生效[1]。
Kinney Drugs, a pharmacy chain operating in Vermont and New York, deployed an artificial intelligence virtual assistant called Burt in May to handle prescription processing and patient communications [1]. The system was developed by third-party company Synerio [1]. However, the implementation has encountered significant problems that have prompted customer complaints and raised privacy concerns.
Patients have reported multiple failures with the AI tool, including prescription delays, incorrect dosage information, and inaccurate notifications [1]. Some customers expressed dissatisfaction with their experience using the system and have cited it as unhelpful, with certain patrons switching to alternative pharmacies due to privacy concerns [1]. The company's privacy policy reveals that protected health information could be used to improve pharmacy operations through AI tools [1], with privacy terms scattered across eleven separate documents [1]. According to Cody Venzke, a senior attorney with the ACLU, technological advancement is outpacing regulatory frameworks [1].
The situation occurs as Vermont enacted data privacy legislation, S.71, which was signed by Governor Phil Scott on June 16 and will take effect in two years [1].